In the last decade, the clinical management of melanoma has undergone a revolutionary transformation due to the introduction of BRAF and MEK inhibitors alongside advancements in immunotherapy, leading to a substantial enhancement in the overall survival rates of patients (9). The gene discussed is BRAF; the disease is melanoma.